Vanguard Group Inc. Raises Position in Lantheus Holdings, Inc. $LNTH

Vanguard Group Inc. increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,952,418 shares of the medical equipment provider’s stock after buying an additional 115,338 shares during the quarter. Vanguard Group Inc. owned about 10.23% of Lantheus worth $356,590,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. purchased a new position in Lantheus in the 3rd quarter worth approximately $65,654,000. Polaris Capital Management LLC acquired a new position in shares of Lantheus during the third quarter worth $32,687,000. Boston Partners boosted its stake in shares of Lantheus by 30.5% in the second quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock valued at $46,432,000 after purchasing an additional 134,781 shares during the period. Raymond James Financial Inc. grew its holdings in Lantheus by 25.1% during the 2nd quarter. Raymond James Financial Inc. now owns 470,678 shares of the medical equipment provider’s stock valued at $38,530,000 after purchasing an additional 94,312 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in Lantheus by 21.3% during the 3rd quarter. Pacer Advisors Inc. now owns 422,180 shares of the medical equipment provider’s stock worth $21,654,000 after buying an additional 74,272 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of LNTH opened at $75.43 on Friday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The firm has a market cap of $5.00 billion, a price-to-earnings ratio of 31.69 and a beta of -0.08. The stock has a 50 day moving average of $67.97 and a 200-day moving average of $60.01.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. During the same period last year, the business posted $1.59 earnings per share. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus News Summary

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results materially beat consensus: reported EPS $1.67 vs. $1.17 expected and revenue $406.8M vs. $367.0M expected; margins and ROE were strong, signalling healthy profitability and execution. Lantheus Q4 results and call
• Positive Sentiment: Analyst upgrade: William Blair raised LNTH from Market Perform to Outperform, which can support buying interest and institutional demand. William Blair upgrade
• Positive Sentiment: Price target increase: Citizens Jmp raised its target to $78, which can reinforce the bullish narrative among some investors. Price target raise
• Neutral Sentiment: Earnings call materials and transcripts are available for investors to review management’s commentary and details behind the beat. These provide color but are not new headline news. Earnings call transcript Earnings presentation
• Negative Sentiment: FY‑2026 guidance was modestly conservative: management gave EPS guidance of $5.00–$5.25 (consensus ~$5.16) and revenue guidance roughly $1.4–$1.5B (consensus ~$1.5B). The EPS range is below some analyst expectations (street average cited ~6.01 in background notes), which could cap upside. Company press release with guidance

Analyst Ratings Changes

A number of research firms have weighed in on LNTH. Mizuho upped their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial increased their price target on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Citigroup restated an “outperform” rating on shares of Lantheus in a report on Tuesday. Citizens Jmp raised their price target on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research report on Tuesday. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $78.83.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.